Natural Killer Cell Therapeutics Market Projected to Reach $5.1 Billion by 2026

The global market for Natural Killer (NK) cell therapeutics is projected to reach $5,096 million by 2026, expanding at a compound annual growth rate (CAGR) of 17.4% from 2019 to 2026. The market was valued at $1,402 million in 2018, according to a report by Allied Market Research.

Growth drivers for the market include the increasing prevalence of diseases such as cancer and gastrointestinal disorders, coupled with rising government expenditure in the healthcare sector and growing awareness of immunotherapy. Ongoing research and development in cancer immunotherapy are also contributing to market expansion by offering advanced treatment features.

The report categorizes the market by therapeutics (NK cell therapies and NK cell directed antibodies), applications (cancer, gastrointestinal diseases, immunoproliferative disorders, and others), and end users (hospitals, research centers, and institutes). The cancer segment held the largest market share in 2018 and is expected to continue its dominance due to the increasing adoption of NK cell therapies for treating various cancers, including acute myeloid leukemia and solid tumors.

North America accounted for the highest market share in 2018, driven by new product innovations. However, the Asia-Pacific region is anticipated to experience the highest growth rate during the forecast period.